These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28967708)

  • 1. Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacological Effect of Orally Administered CORT125134: An Adaptive, Double-Blind, Randomized, Placebo-Controlled Phase 1 Clinical Study.
    Hunt H; Donaldson K; Strem M; Zann V; Leung P; Sweet S; Connor A; Combs D; Belanoff J
    Clin Pharmacol Drug Dev; 2018 May; 7(4):408-421. PubMed ID: 28967708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug.
    Richard M; Kaufmann P; Ort M; Kornberger R; Dingemanse J
    CNS Drugs; 2020 Mar; 34(3):311-323. PubMed ID: 31994022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, Safety, and Tolerability of Multiple Doses of the Novel Oxytocin Receptor Antagonist Cligosiban in Development for Premature Ejaculation: Two Randomized Clinical Trials in Healthy Subjects.
    Muirhead GJ; Osterloh IH; Whaley S; van den Berg F
    J Sex Med; 2019 Feb; 16(2):213-222. PubMed ID: 30612858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-man study of ACT-709478, a novel selective triple T-type calcium channel blocker.
    Richard M; Kaufmann P; Kornberger R; Dingemanse J
    Epilepsia; 2019 May; 60(5):968-978. PubMed ID: 31004346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, Safety, and Tolerability of Single- and Multiple-Dose Once-Daily Baricitinib in Healthy Chinese Subjects: A Randomized Placebo-Controlled Study.
    Zhao X; Sheng XY; Payne CD; Zhang X; Wang F; Cui YM
    Clin Pharmacol Drug Dev; 2020 Nov; 9(8):952-960. PubMed ID: 32945153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability, pharmacokinetics, and pharmacodynamics of single-dose almorexant, an orexin receptor antagonist, in healthy elderly subjects.
    Hoever P; Hay J; Rad M; Cavallaro M; van Gerven JM; Dingemanse J
    J Clin Psychopharmacol; 2013 Jun; 33(3):363-70. PubMed ID: 23609389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, Tolerability, and Pharmacokinetics of FAAH Inhibitor BIA 10-2474: A Double-Blind, Randomized, Placebo-Controlled Study in Healthy Volunteers.
    Rocha JF; Santos A; Gama H; Moser P; Falcão A; Pressman P; Wallace Hayes A; Soares-da-Silva P
    Clin Pharmacol Ther; 2022 Feb; 111(2):391-403. PubMed ID: 33998672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers.
    Weisel K; Scott NE; Tompson DJ; Votta BJ; Madhavan S; Povey K; Wolstenholme A; Simeoni M; Rudo T; Richards-Peterson L; Sahota T; Wang JG; Lich J; Finger J; Verticelli A; Reilly M; Gough PJ; Harris PA; Bertin J; Wang ML
    Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability and pharmacokinetics of a new P-glycoprotein inhibitor, HM30181, in healthy Korean male volunteers: single- and multiple-dose randomized, placebo-controlled studies.
    Kim TE; Gu N; Yoon SH; Cho JY; Park KM; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2012 Feb; 34(2):482-94. PubMed ID: 22284902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study.
    Takahashi S; Fujiwara Y; Nakano K; Shimizu T; Tomomatsu J; Koyama T; Ogura M; Tachibana M; Kakurai Y; Yamashita T; Sakajiri S; Yamamoto N
    Cancer Sci; 2021 Jun; 112(6):2361-2370. PubMed ID: 33686772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, Tolerability and Pharmacokinetics of FAAH Inhibitor V158866: A Double-Blind, Randomised, Placebo-Controlled Phase I Study in Healthy Volunteers.
    Pawsey S; Wood M; Browne H; Donaldson K; Christie M; Warrington S
    Drugs R D; 2016 Jun; 16(2):181-91. PubMed ID: 26987975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis.
    Banfield C; Scaramozza M; Zhang W; Kieras E; Page KM; Fensome A; Vincent M; Dowty ME; Goteti K; Winkle PJ; Peeva E
    J Clin Pharmacol; 2018 Apr; 58(4):434-447. PubMed ID: 29266308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, Safety, and Tolerability of Selonsertib, an Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitor, Following First-in-Human Single and Multiple Ascending Doses in Healthy Subjects.
    Nelson CH; Etchevers K; Yi S; Breckenridge D; Hepner M; Patel U; Ling J; Mathias A
    Clin Pharmacokinet; 2020 Sep; 59(9):1109-1117. PubMed ID: 32333325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FKBP5 mRNA Expression Is a Biomarker for GR Antagonism.
    Bali U; Phillips T; Hunt H; Unitt J
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4305-4312. PubMed ID: 27459525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of pimecrolimus, a novel nonsteroid anti-inflammatory drug, after single and multiple oral administration.
    Scott G; Osborne SA; Greig G; Hartmann S; Ebelin ME; Burtin P; Rappersberger K; Komar M; Wolff K
    Clin Pharmacokinet; 2003; 42(14):1305-14. PubMed ID: 14606933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers.
    Addy C; Rothenberg P; Li S; Majumdar A; Agrawal N; Li H; Zhong L; Yuan J; Maes A; Dunbar S; Cote J; Rosko K; Van Dyck K; De Lepeleire I; de Hoon J; Van Hecken A; Depré M; Knops A; Gottesdiener K; Stoch A; Wagner J
    J Clin Pharmacol; 2008 Jun; 48(6):734-44. PubMed ID: 18508950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single- and multiple-dose pharmacokinetics of samidorphan, a novel opioid antagonist, in healthy volunteers.
    Turncliff R; DiPetrillo L; Silverman B; Ehrich E
    Clin Ther; 2015 Feb; 37(2):338-48. PubMed ID: 25456560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers.
    Pieniaszek HJ; Sy SK; Ebling W; Fossler MJ; Cain VA; Mondick JT; Ma S; Kornhauser DM
    J Clin Pharmacol; 2002 Jul; 42(7):738-53. PubMed ID: 12092741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple-dose pharmacokinetics, pharmacodynamics and tolerability of the oral ET(A) endothelin-receptor antagonist SPP301 in man.
    Dieterle W; Mann J; Kutz K
    Int J Clin Pharmacol Ther; 2005 Apr; 43(4):178-86. PubMed ID: 15966464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.